Preclinical Studies for Gene Therapy of Duchenne Muscular Dystrophy

Odom, Guy L.; Banks, Glen B.; Schultz, Brian R.; Gregorevic, Paul; Chamberlain, Jeffrey S.
September 2010
Journal of Child Neurology;Sep2010, Vol. 25 Issue 9, p1149
Academic Journal
The muscular dystrophies are a diverse group of genetic disorders without an effective treatment. Because they are caused by mutations in various genes, the most direct way to treat them involves correcting the underlying gene defect (ie, gene therapy). Such a gene therapy approach involves delivering a therapeutic gene cassette to essentially all the muscles of the body in a safe and efficacious manner. The authors describe gene delivery methods using vectors derived from adeno-associated virus that are showing great promise in preclinical studies for treatment of Duchenne muscular dystrophy. It is hoped that variations on these methods might be applicable for most, if not all, of the different types of muscular dystrophy.


Related Articles

  • GENE REPAIR.  // Science Teacher;Sep2000, Vol. 67 Issue 6, p17 

    Reports on the findings of a study on the use of gene therapy to treat Duchenne muscular dystrophy. Difficulty of developing gene therapy for the condition; Causes of the disease.

  • ADVANCES IN DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY. van Deutekom, Judith C.T.; van Ommen, Gert-Jan B. // Nature Reviews Genetics;Oct2003, Vol. 4 Issue 10, p774 

    Provides information on gene therapy for Duchene muscular dystrophy. Proneness of the X-linked dystrophin gene to rearrange and recombine events that cause mutations; Means to replace a defective dystrophin gene; Overview of animal models for Duchenne muscular dystrophy gene-therapy studies.

  • Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast... Gussoni, E.; Pavlath, G.K. // Nature;4/2/1992, Vol. 356 Issue 6368, p435 

    Tests the possibility of gene delivery by transplantation of normal myoblasts as a treatment of the primary defect that causes Duchenne muscular dystrophy. Lack of the muscle protein dystrophin as the primary defect in Duchenne muscular dystrophy; Muscle degenerative disorders; Methods;...

  • Gene Studies in Newborn Males With Duchenne Muscular Dystrophy Detected by Neonatal Screening.  // JAMA: Journal of the American Medical Association;4/14/89, Vol. 261 Issue 14, p2052 

    Presents an abstract of the article 'Gene Studies in Newborn Males With Duchenne Muscular Dystrophy Detected by Neonatal Screening.'

  • The gene and its product. Mandel, J.L. // Nature;6/22/1989, Vol. 339 Issue 6226, p584 

    Discusses several recent articles on the dystrophin gene, whose malfunction is responsible for the Duchenne and Becker muscular dystrophies. Localization and function; Deletions and diagnosis; Animals, models and therapy.

  • Corticosteroids for Children with Duchenne’s Muscular Dystrophy. T., H. // School Health Alert;Jan2014, Vol. 29 Issue 5, p7 

    The article offers information on a study on the effectiveness of corticosteroids on children with Duchenne's muscular dystrophy.

  • Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal. Wong, Brenda L.Y.; Christopher, Caroline // Journal of Child Neurology;Mar2002, Vol. 17 Issue 3, p183 

    Duchenne muscular dystrophy is the most common and most severe form of childhood muscular dystrophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advances made in the understanding of the molecular genetics...

  • Screening of the Newborn for Duchenne Muscular Dystrophy.  // British Medical Journal;5/24/1975, Vol. 2 Issue 5968, p403 

    Proposes a method for the routine screening of newborn male infants for duchenne muscular dystrophy. Significance of serum creatine phosphokinase activity in detecting gene carriers; Details of duchenne muscular dystrophy; Treatment for duchenne; Management of patients with neuromuscular diseases.

  • Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases. Consalvi, Silvia; Saccone, Valentina; Giordani, Lorenzo; Minetti, Giulia; Mozzetta, Chiara; Puri, Pier Lorenzo // Molecular Medicine;May/Jun2011, Vol. 17 Issue 5/6, p457 

    Histone deacetylases inhibitors (HDACi) include a growing number of drugs that share the ability to inhibit the enzymatic activity of some or all the HDACs. Experimental and preclinical evidence indicates that these epigenetic drugs not only can be effective in the treatment of malignancies,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics